naproxen has been researched along with ketanserin in 6 studies
| Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) | Studies (ketanserin) | Trials (ketanserin) | Recent Studies (post-2010) (ketanserin) |
|---|---|---|---|---|---|
| 4,551 | 1,057 | 1,429 | 3,094 | 335 | 283 |
| Protein | Taxonomy | naproxen (IC50) | ketanserin (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0016 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0021 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| 5-hydroxytryptamine receptor 1D | Homo sapiens (human) | 0.265 | |
| 5-hydroxytryptamine receptor 1B | Homo sapiens (human) | 6.5 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0184 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0027 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0016 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.29 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.015 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 1.8 | |
| Synaptic vesicular amine transporter | Homo sapiens (human) | 0.18 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 0.001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrews, PR; Craik, DJ; Martin, JL | 1 |
| Andersson, K; Borg, P; Frostell-Karlsson, A; Hämäläinen, M; Karlsson, R; Remaeus, A; Roos, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
6 other study(ies) available for naproxen and ketanserin
| Article | Year |
|---|---|
Functional group contributions to drug-receptor interactions.
Topics: Animals; Calorimetry; Kinetics; Models, Biological; Protein Binding; Receptors, Cell Surface; Receptors, Drug; Structure-Activity Relationship | 1984 |
Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels.
Topics: Binding Sites; Biosensing Techniques; Digitoxin; Drug Stability; Humans; Molecular Weight; Naproxen; Orosomucoid; Pharmaceutical Preparations; Protein Binding; Quinine; Rifampin; Ritonavir; Serum Albumin; Solvents; Warfarin | 2000 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |